Sun Pharma Advanced Research Company Ltd - Stock Valuation and Financial Performance

BSE: 532872 | NSE: SPARC | Business Support | Small Cap

Sun Pharma Adv. Res Share Price

409.55 -21.55 -5.00%
as on 12-Apr'24 16:59

DeciZen - make an informed investing decision on Sun Pharma Adv. Res

Overall Rating
Bole Toh

1. Quality

2. Valuation

Overvalued

3. Price Trend

Sun Pharma Advanced Research Company stock performance -

mw4me loader
P/E Ratio (SA):
0.00
Market Cap:
13,290.8 Cr.
52-wk low:
178.1
52-wk high:
474

Is Sun Pharma Advanced Research Company Ltd an attractive stock to invest in?

1. Is Sun Pharma Advanced Research Company Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Sun Pharma Advanced Research Company Ltd is a below average quality company.

2. Is Sun Pharma Advanced Research Company Ltd undervalued or overvalued?

The key valuation ratios of Sun Pharma Advanced Research Company Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is Sun Pharma Advanced Research Company Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Sun Pharma Advanced Research Company Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

10 Year X-Ray of Sun Pharma Adv. Res:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Sun Pharma Advanced Research Company Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
ROCE % 18%-31.8%-71.3%-95.7%-134.4%-59.5%-177.6%-264%-233.7%-69.7%-
Value Creation
Index
0.3-3.3-6.3-8.1-11.0-5.3NANANA-6.2-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 16715616118178.318376.8253137239107
Sales YoY Gr.--6.8%3.6%12.2%-56.8%133.7%-58%229.3%-45.7%74%-
Adj EPS 1.1-1.7-3-4.9-9.3-5.5-11.8-5.9-7.6-6.8-11.2
YoY Gr.--252.3%NANANANANANANANA-
BVPS (₹) 5.84.21.26.43.711.3-0.7-6.4-7.515.87.2
Adj Net
Profit
26.1-39.6-69.8-120-234-144-309-153-206-221-363
Cash Flow from Ops. 36.9-41.2-44.2-128-183-172-211-152-208-69.1-
Debt/CF from Ops. 0.1-0.1-1.3-0-0-0-0.3-1.5-0.40-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 4.1%25%46%74%
Adj EPS -222.6%NANANA
BVPS11.7%33.6%NANA
Share Price 10.2% 17.5% 36.2% 118.7%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
Return on
Equity %
21-33.2-106.1-126.7-136.6-60-222.9164.2301-81.3-97.6
Op. Profit
Mgn %
20.1-22.5-39-67.7-310-79.1-397.7-53.4-135.5-88.7-361.7
Net Profit
Mgn %
15.6-25.4-43.3-66.5-299.2-78.9-402.7-60.7-150.3-92.6-340.7
Debt to
Equity
001.9000-3.6-1.4-0.40-
Working Cap
Days
161200163210641254554175351339685
Cash Conv.
Cycle
-63-80-130-170-113-272-254-119-60-85375

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 45.95%

Return on Equity is Poor

Sales growth is not so good in last 4 quarters at -12.30%

Latest Financials - Sun Pharma Advanced Research Company Ltd.

Standalone Consolidated
TTM EPS (₹) -11.2 -
TTM Sales (₹ Cr.) 107 -
BVPS (₹.) 7.2 -
Reserves (₹ Cr.) 200 -
P/BV 57.28 -
PE 0.00 -
From the Market
52 Week Low / High (₹) 178.10 / 474.00
All Time Low / High (₹) 38.44 / 593.93
Market Cap (₹ Cr.) 13,291
Equity (₹ Cr.) 32.5
Face Value (₹) 1
Industry PE 47.1

Management X-Ray of Sun Pharma Adv. Res:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *2.292.182.181.651.022.782.782.782.782.78
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Sun Pharma Adv. Res

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Sales1671561611817818377253137239
Operating Expenses 134191224304321334387388324453
Manufacturing Costs20233134372336214139186
Material Costs0000000000
Employee Cost 4046578410181939298107
Other Costs 731221371851832302588287160
Operating Profit 33-35-63-123-243-151-310-135-187-214
Operating Profit Margin (%) 20.1%-22.5%-39.2%-67.8%-310.0%-82.7%-403.0%-53.4%-136.0%-89.6%
Other Income 103314514105711
Interest 602200311138
Depreciation 4788889111012
Exceptional Items 00004900000
Profit Before Tax 34-40-70-119-197-145-312-151-203-223
Tax 4000000000
Profit After Tax 30-40-70-119-197-145-312-151-203-223
PAT Margin (%) 18.2%-25.4%-43.4%-65.8%-251.0%-79.5%-406.0%-59.7%-148.0%-93.2%
Adjusted EPS (₹)1.3-1.7-3.0-4.8-7.9-5.6-11.9-5.8-7.5-6.9
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23

Equity and Liabilities

Shareholders Fund 1391003015893296-19-168-203513
Share Capital 24242425252626262732
Reserves 11676613368270-45-194-230480
Minority Interest0000000000
Debt54553216619300
Long Term Debt433221611300
Short Term Debt1052000608000
Trade Payables30275894102831599172148
Others Liabilities 141623211161866114411169
Total Liabilities 188147167277313398273230280830

Fixed Assets

Gross Block8796107776780136123133146
Accumulated Depreciation2230378152332324140
Net Fixed Assets6467706952581049192106
CWIP 10113243252627
Investments 700101082118612291
Inventories0000000000
Trade Receivables2820939181016182833
Cash Equivalents 717137011091112
Others Assets8143748713195112101121262
Total Assets 188147167277313398273230280830

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Cash Flow From Operating Activity 37-41-44-128-183-172-211-152-208-69
PBT 34-40-70-119-246-145-312-151-203-223
Adjustment 159-14-22949177
Changes in Working Capital 10-4301320-0102-48-26141
Tax Paid -8-3-14-21-10-5-10-255
Cash Flow From Investing Activity 4453-13-7-105-1021552-29-548
Capex -4-8-12-8-18-13-54-1-25-15
Net Investments 9570-9-88-932093-5-535
Others -4854-111130002
Cash Flow From Financing Activity -81-15119422427455159229617
Net Proceeds from Shares 10225013336700167703
Net Proceeds from Borrowing -1-1-1-10-1010600
Interest Paid -90-2-300-2-8-14-8
Dividend Paid 0000000000
Others -72051-5291-92576177-78
Net Cash Flow 011-760-63009-8-1
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Ratios
ROE (%)24.62-33.17-109.16-127.4-156.84-74.72N/AN/AN/A-143.72
ROCE (%)24.02-31.74-71.37-94.66-113.05-59.95N/AN/AN/A-69.44
Asset Turnover Ratio0.840.931.030.820.270.510.231.010.540.43
PAT to CFO Conversion(x)1.23N/AN/AN/AN/AN/AN/AN/AN/AN/A
Working Capital Days
Receivable Days585633481322862246046
Inventory Days0000000000
Payable Days0000000000

Sun Pharma Advanced Research Company Ltd Stock News

Sun Pharma Advanced Research Company Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Sun Pharma Adv. Res on 12-Apr-2024 16:59 is ₹409.6.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 12-Apr-2024 16:59 the market cap of Sun Pharma Adv. Res stood at ₹13,290.8.
The latest P/E ratio of Sun Pharma Adv. Res as of 12-Apr-2024 16:59 is 0.00.
The latest P/B ratio of Sun Pharma Adv. Res as of 12-Apr-2024 16:59 is 57.28.
The 52-week high of Sun Pharma Adv. Res is ₹474.0 and the 52-week low is ₹178.1.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Sun Pharma Adv. Res is ₹106.7 ( Cr.) .

About Sun Pharma Advanced Research Company Ltd

Sun Pharma Advanced Research Company (SPARC) is a clinical stage bio-pharmaceutical company focused on continuously improving standards of care for patients globally, through innovation in therapeutics and delivery. SPARC was formed in 2007 through a demerger from SUN PHARMA, a global leader in speciality generics. It strive to build an enduring innovation engine built on strong scientific execution, high value analytics and aggressive portfolio management. A robust mix of internal ideation and strategic partnering with academic innovators and bio-pharma entrepreneurs fuel engine with potentially high impact ideas.

The company partner with thought-leading clinicians across the world for ideas and access. Innovation through integration of partner knowledge and efficient internal execution shapes future. SPARC is a vibrant innovation community spread over three locations globally. It endeavour to develop a meritocracy which takes pride in continuous learning and re-invention. SPARC is a responsible public company committed to maintaining highest standards of ethics and transparency.

Business area of the company

The company is engaged in the pharmaceutical research and development. The company’s core focus is innovation and new product development for global markets. SPARC undertakes projects in research and technology for new chemical entities (NCE’s) or new molecules, and novel drug delivery systems (NDDS).

Products

  • Therapeutic Focus (Oncology, Neuro Degeneration, Ophthalmology, Dermatology)
  • Delivery Technologies (Gastro Retentive Innovative Device, Wrap Matrix, Abuse Deterrent Program, Nanotecton Technology, Dry Powder Inhalation, TearAct, Lipixelle, Gel Free Reservoir)
  • Research Programs (Taclantis, SCO - 088, SCD - 044, SCC - 138, SCO - 120)

Milestones

  • 2006: SPARC is founded in Vadodara, India
  • 2007: Innovative R&D business was demerged from Sun Pharmaceutical Industries Limited to focus on innovative drug research
  • 2007: Listed on Bombay Stock Exchange and National Stock Exchange of India
  • 2012: 1st NDA filed with USFDA for Elepsia XR
  • 2012: Raised Rs. 200 crore through Rights Issue
  • 2013: Filed NDA for Xelpros with USFDA
  • 2014: US rights for Xelpros licensed to a subsidiary of Sun Pharma
  • 2015: Entered into research collaboration in the field of Oncology with US University
  • 2015: Launched Bevetex (PICS) in India
  • 2016: Raised Rs. 250 crore through Rights Issue
  • 2017: Secured funding of up to Rs. 500 crore through Preferential Allotment of warrants convertible into equity shares
  • 2018: Entered into collaboration with Schrödinger to accelerate Neurodegeneration Drug Development Programs
  • 2018: Positive top line results reported for the pivotal bioequivalence study of Taclantis (Paclitaxel Injection Concentrate for Suspension)
  • 2018: US FDA approved Xelpros for the treatment of open-angle glaucoma or ocular hypertension
  • 2019: Entered into licensing agreement with Bioprojet SCR to acquire exclusive rights for Investigational Medicinal Product, SCD-044
  • 2019: Entered into a licensing deal with China Medical System Holdings Limited (CMS) to develop and commercialize multiple products in Mainland China, Hong Kong, Macao, and Taiwan
  • 2019: Orphan Drug Designation received from the US FDA for SPARCs neonatal seizures drug, Phenobarbital
  • 2019: Orphan Drug Designation received from the US FDA for SPARCs Chronic Myeloid Leukemia drug, SCO-088
  • 2019: NDA for Taclantis (Paclitaxel Injection Concentrate for Suspension) accepted by US FDA for review
  • 2019: Entered into collaboration with HitGen for Innovative Drug Discovery Research
  • 2020: Entered into a worldwide license agreement for SCD-044 with Sun Pharma
  • 2020: Entered into collaboration with the University of Michigan to kickstart research and development of potential new medications
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.